JP2012504649A5 - - Google Patents

Download PDF

Info

Publication number
JP2012504649A5
JP2012504649A5 JP2011530261A JP2011530261A JP2012504649A5 JP 2012504649 A5 JP2012504649 A5 JP 2012504649A5 JP 2011530261 A JP2011530261 A JP 2011530261A JP 2011530261 A JP2011530261 A JP 2011530261A JP 2012504649 A5 JP2012504649 A5 JP 2012504649A5
Authority
JP
Japan
Prior art keywords
rifaximin
subject
administration
episodes
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011530261A
Other languages
English (en)
Japanese (ja)
Other versions
JP6037615B2 (ja
JP2012504649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/059321 external-priority patent/WO2010040020A1/en
Publication of JP2012504649A publication Critical patent/JP2012504649A/ja
Publication of JP2012504649A5 publication Critical patent/JP2012504649A5/ja
Application granted granted Critical
Publication of JP6037615B2 publication Critical patent/JP6037615B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011530261A 2008-10-02 2009-10-02 肝性脳症を治療する方法 Active JP6037615B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10234908P 2008-10-02 2008-10-02
US61/102,349 2008-10-02
PCT/US2009/059321 WO2010040020A1 (en) 2008-10-02 2009-10-02 Methods of treating hepatic encephalopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015103724A Division JP2015166381A (ja) 2008-10-02 2015-05-21 肝性脳症を治療する方法

Publications (3)

Publication Number Publication Date
JP2012504649A JP2012504649A (ja) 2012-02-23
JP2012504649A5 true JP2012504649A5 (enExample) 2012-11-22
JP6037615B2 JP6037615B2 (ja) 2016-12-07

Family

ID=42073897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011530261A Active JP6037615B2 (ja) 2008-10-02 2009-10-02 肝性脳症を治療する方法
JP2015103724A Pending JP2015166381A (ja) 2008-10-02 2015-05-21 肝性脳症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015103724A Pending JP2015166381A (ja) 2008-10-02 2015-05-21 肝性脳症を治療する方法

Country Status (21)

Country Link
US (12) US20100204173A1 (enExample)
EP (4) EP3628319B1 (enExample)
JP (2) JP6037615B2 (enExample)
CN (1) CN102245615A (enExample)
AU (1) AU2009298389C1 (enExample)
BR (1) BRPI0920465A2 (enExample)
CA (1) CA2739436C (enExample)
CY (1) CY1122806T1 (enExample)
DK (2) DK3628319T3 (enExample)
ES (2) ES2972135T3 (enExample)
FI (1) FI3628319T3 (enExample)
HR (2) HRP20240317T1 (enExample)
HU (2) HUE048293T2 (enExample)
IL (1) IL212055A0 (enExample)
LT (2) LT2350096T (enExample)
MX (2) MX364102B (enExample)
PL (2) PL2350096T3 (enExample)
PT (2) PT2350096T (enExample)
SI (2) SI2350096T1 (enExample)
SM (2) SMT202400116T1 (enExample)
WO (1) WO2010040020A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
MX364102B (es) 2008-10-02 2019-04-12 Salix Pharmaceuticals Ltd Medicamentos para usarse en el tratamiento de la encefalopatía hepática.
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BRPI1010028A2 (pt) * 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
RU2571268C2 (ru) * 2009-06-15 2015-12-20 Саликс Фармасьютикалз, Лтд. Модуляция системного воздействия рифаксимина
CA2778181C (en) 2009-10-26 2024-05-28 Thomas Julius Borody Therapy for enteric infections
AU2011286165B2 (en) 2010-08-04 2016-10-20 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
PL2773205T3 (pl) 2011-11-02 2024-09-02 Salix Pharmaceuticals, Inc. Ryfaksymina w leczeniu ustępującej biegunki z przewagą zespołu jelita drażliwego
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
MX2015003107A (es) * 2012-09-13 2015-09-10 Salix Pharmaceuticals Inc Metodos para mejorar la supervivencia a largo plazo y reducir los porcentajes de readmision a hospitalizacion para personas que padecen encefalopatia hepatica.
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014107657A2 (en) * 2013-01-04 2014-07-10 Kohn Kenneth I Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2014176632A1 (en) * 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
US20160339040A1 (en) 2014-01-29 2016-11-24 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
PL3143027T3 (pl) 2014-05-12 2019-11-29 Alfasigma Spa Nowe solwatowane krystaliczne postaci rifaksyminy, ich wytwarzanie, kompozycje i zastosowania
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
KR20180026376A (ko) 2015-05-14 2018-03-12 크레스토보 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
DK3297644T3 (da) 2015-05-22 2022-04-11 Univ Arizona State Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer
CA3010865A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
CN110072525B (zh) 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
CN106822125A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的新用途
CN106822119A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑硝基咪唑偶联分子的新用途
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
AR114140A1 (es) 2017-11-10 2020-07-29 Cosmo Technologies Ltd Composiciones orales de rifamicina sv
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
WO2020245214A1 (en) * 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
JP2022541795A (ja) 2019-07-19 2022-09-27 フィンチ セラピューティクス ホールディングス エルエルシー 胃腸障害の治療のための方法および産物
CN115715193A (zh) * 2020-03-24 2023-02-24 博士医疗爱尔兰有限公司 用于治疗显性肝性脑病的利福昔明的固体分散体
US20250345400A1 (en) * 2022-05-18 2025-11-13 Virginia Commonwealth University Methods for treatment of cognitive impairment in cirrhosis patients
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132910A (en) 1962-03-26 1964-05-12 Eastman Kodak Co Cabinetry structure
US3132908A (en) 1962-04-02 1964-05-12 Carrier Corp Thrust bearing construction
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
US4343785A (en) 1981-08-10 1982-08-10 Basf Wyandotte Corporation Gel dentifrice compositions
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
ES2114502B1 (es) 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
AU4414497A (en) 1996-09-13 1998-04-02 University Technology Corporation Biocompatible cationic detergents and uses therefor
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US20020028764A1 (en) 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
WO2004019907A1 (en) * 2002-08-29 2004-03-11 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7256202B2 (en) 2003-12-31 2007-08-14 Halow George M Composition and method for treatment of hepatic encephalopathy
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
CN101594885B (zh) 2006-03-09 2017-07-18 萨利克斯药品公司 利福昔明抗直肠功能障碍制剂
EP2049087A2 (en) 2006-07-21 2009-04-22 LAB International SRL Hydrophilic abuse deterrent delivery system
US20100069421A1 (en) 2006-08-02 2010-03-18 Doug Bettenhausen Compositions and methods for the treatment of radiation proctosigmoitis
KR20150132214A (ko) 2006-08-02 2015-11-25 샐릭스 파마슈티컬스 인코포레이티드 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
JP2010504314A (ja) 2006-09-22 2010-02-12 シプラ・リミテッド リファキシミン
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
MY158257A (en) * 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
RU2519649C2 (ru) * 2008-02-26 2014-06-20 Саликс Фармасьютикалз, Лтд. Способы лечения заболеваний кишечника
MX364102B (es) * 2008-10-02 2019-04-12 Salix Pharmaceuticals Ltd Medicamentos para usarse en el tratamiento de la encefalopatía hepática.
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BRPI1010028A2 (pt) * 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
HRP20180016T1 (hr) 2010-08-26 2018-02-09 Boehringer Ingelheim International Gmbh Postupci primjene egfr-inhibitora
KR20130027255A (ko) * 2011-09-07 2013-03-15 삼성전자주식회사 키 조립체 및 이를 구비한 회전식 입력 장치
SG11201401471PA (en) 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
US10234908B2 (en) 2014-04-29 2019-03-19 Hewlett-Packard Develoment Company, L.P. Hinge assembly for a computing device
US9628828B2 (en) * 2014-12-15 2017-04-18 Cable Television Laboratories, Inc. Software defined networking in a cable TV system
WO2016193860A1 (en) 2015-06-04 2016-12-08 Pfizer Inc. Solid dosage forms of palbociclib

Similar Documents

Publication Publication Date Title
JP2012504649A5 (enExample)
Hoy et al. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation
Mallikaarjun et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study
JP2014528474A5 (enExample)
Ishigooka et al. Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study
Hamza et al. Isolated pulmonic valve infective endocarditis: a persistent challenge
Cutler et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
Ma et al. Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients
CN105579037A (zh) 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
CN118557572A (zh) 苯并咪唑衍生物用于夜间酸突破的用途
Citrome et al. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?
Navarro Improving medication compliance in patients with depression: Use of orodispersible tablets
Burris et al. Dosage adjustments related to young or old age and organ impairment
Yatham et al. A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder
Winkelman et al. Current patterns and future directions in the treatment of insomnia
Youn et al. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study
Metzger et al. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits
AU2005205880B2 (en) Compounds for the sustained reduction of body weight
US20200281884A1 (en) Use of a Benzoate Containing Composition to Treat Glycine Encephalopathy
Gupta et al. Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study
Elsibai et al. Management of Parkinson’s disease psychosis
US20170056459A1 (en) Compositions and Methods for Aiding Phase 3 Recovery After Anesthesia
Diarra et al. Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis
Boussery et al. Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems
Markham-Abedi et al. A case report with ziprasidone-induced catatonic symptoms